STAAR Surgical (STAA) awards director 7,524 stock options vesting in 2026

Rhea-AI Filing Summary

STAAR Surgical director Richard T. LeBuhn received a grant of stock options as compensation. On March 6, 2026, he was awarded options to purchase 7,524 shares of common stock at an exercise price of $18.46 per share under the company’s Amended and Restated Omnibus Equity Incentive Plan.

The options vest and become exercisable on the earlier of June 18, 2026 or the company’s 2026 annual meeting of shareholders, as long as he continues serving the company. The options expire on March 5, 2036, and following this grant he holds 7,524 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LeBuhn Richard T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	OPTION TO PURCHASE COMMON STOCK	7,524	$0.00	--

Holdings After Transaction: OPTION TO PURCHASE COMMON STOCK — 7,524 shares (Direct)

Footnotes (1)

1. These options will vest and become exercisable on the earlier of: (a) June 18, 2026 and (b) the date of STAAR Surgical Company's (the "Issuer") 2026 annual meeting of shareholders, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer. These options were granted to the Reporting Person by the Issuer on March 6, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBuhn Richard T.

(Last) (First) (Middle)

C/O BROADWOOD CAPITAL, INC.

156 WEST 56TH STREET, 3RD FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
OPTION TO PURCHASE COMMON STOCK	$18.46	03/06/2026		A		7,524		(1)	03/05/2036	COMMON STOCK	7,524	$0(2)	7,524	D

Explanation of Responses:

1. These options will vest and become exercisable on the earlier of: (a) June 18, 2026 and (b) the date of STAAR Surgical Company's (the "Issuer") 2026 annual meeting of shareholders, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer.

2. These options were granted to the Reporting Person by the Issuer on March 6, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.

	Richard T. LeBuhn, /s/ Richard T. LeBuhn	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STAAR Surgical (STAA) report for Richard T. LeBuhn?

STAAR Surgical reported that director Richard T. LeBuhn received a grant of 7,524 stock options. The options were awarded on March 6, 2026 as director compensation under the company’s Amended and Restated Omnibus Equity Incentive Plan, giving him the right to purchase common shares.

What are the key terms of Richard T. LeBuhn’s new STAAR Surgical (STAA) stock options?

The grant covers options on 7,524 shares of STAAR Surgical common stock at an exercise price of $18.46 per share. The options expire on March 5, 2036, providing a long-term window for potential exercise if vesting and continued service conditions are satisfied.

When do Richard T. LeBuhn’s STAAR Surgical (STAA) options vest?

The options vest and become exercisable on the earlier of June 18, 2026 or the date of STAAR Surgical’s 2026 annual shareholder meeting. Vesting in both cases depends on LeBuhn’s continuous service with the company through the applicable vesting date, as described in the grant footnotes.

Why were these STAAR Surgical (STAA) options granted to Richard T. LeBuhn?

The options were granted as director compensation pursuant to STAAR Surgical’s Amended and Restated Omnibus Equity Incentive Plan. This indicates the award is part of the company’s established equity-based compensation program for board members, aligning director incentives with shareholder interests over the long term.

How many STAAR Surgical (STAA) options does Richard T. LeBuhn hold after this grant?

After this transaction, Richard T. LeBuhn holds 7,524 stock options directly, according to the filing’s post-transaction holdings figure. This amount matches the size of the March 6, 2026 award, indicating this Form 4 reflects a single new director compensation grant.